Denali Capital Acquisition CORP DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Semnur Pharmaceuticals, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 25, 2026.
Denali Capital Acquisition Corp. has secured a $20 million private investment in public equity (PIPE) financing from JW Capital Securities Limited to support its merger with Semnur Pharmaceuticals, Inc.
Denali Capital Acquisition Corp. is seeking shareholder approval to extend the deadline for completing a business combination from April 11, 2025, to December 11, 2025, to allow more time to finalize a deal.
DEF 14A: Denali Capital Acquisition Corp. Seeks Shareholder Approval for Extension Amid Merger Termination
Denali Capital Acquisition Corp. is seeking shareholder approval to extend the deadline for completing a business combination to April 11, 2025, after terminating its merger agreement with Longevity Biomedical, Inc.